National Bank of Canada
BBIO icon

National Bank of Canada’s BridgeBio Pharma BBIO Stock Holding History

National Bank of Canada’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-346
Closed -$4K – 2781
2022
Q1 		$4K Hold
346
– – ﹤0.01% 2586
2021
Q4 		$6K Buy
+346
New +$14.6K ﹤0.01% 2488

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's BBIO Position: Q2 2022 in Review

National Bank of Canada sold out of BridgeBio Pharma (BBIO) in Q2 2022, closing a stake of 346 shares — an estimated $4K sold.

National Bank of Canada first reported a position in BBIO in Q4 2021 and held it in 2 quarters. The position peaked at $6K in Q4 2021. 164 funds tracked by Wall St. Rank hold BBIO as of Q2 2022.

  • National Bank of Canada reported no remaining BridgeBio Pharma position as of Q2 2022 after selling out during the quarter.
  • National Bank of Canada sold 346 BridgeBio Pharma shares in Q2 2022, an estimated $4K.
  • National Bank of Canada first reported a position in BridgeBio Pharma in Q4 2021 and held it in 2 quarters.
  • National Bank of Canada's BridgeBio Pharma position peaked at $6K in Q4 2021.
  • 164 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2022.

Based on National Bank of Canada's 13F filing for Q2 2022, filed 28 Jul 2022.